

Univ.-Prof. Dr. med. Miriam Wittmann

*20.04.1970

Professor of Inflammatory Skin Diseases (W3)

Department of Dermatology
University Medical Center of the
Johannes Gutenberg University Mainz
D-55131 Mainz, Langenbeckstr. 1

Tel: +49-6131-17 3792

Miriam.Wittmann@unimedizin-mainz.de**Academia**

07/2013	Fellow of the Higher Education Academy (FHEA)
01/12/2012	Postgraduate Certificate in Learning and Teaching in Higher Education (Route 2 – by portfolio), University of Leeds
July 07, 2007	Venia legendi (Habilitation) for Dermatology & Venereology, Hannover, Germany
April 24, 2005	Board certification in Dermatology (German Specialist Register)
10/2005	Positive evaluation of “Junior-Professorship” Hannover, Germany
06 May 1999	MD thesis in the field of the autoimmune pathogenesis of type I diabetes; Diabetes Research Institute, Heinrich-Heine University, Düsseldorf

Career

05/2022 – today	Professor in Inflammatory Skin Diseases, Johannes Gutenberg University, Mainz, Department of Dermatology
04/2012 – 04/2022	Associate Professor in Inflammatory Skin Diseases, Specialist Doctor in Dermatology, University of Leeds & Department of Dermatology (NHS Foundation Trust, Bradford) & Leeds Musculoskeletal Biomedical Research Unit (LMBRU; NIHR)
11/2008 – 03/2012	Lecturer in Immunology, Faculty of Biological Sciences, University of Leeds
03/2003 – 10/2008	Head of the outpatient clinic for autoimmune skin diseases at Hannover Medical School (jointly with Prof. T. Werfel)
12/2002 – 10/2008	Position as “Junior Professor” for Chronic Inflammatory Skin Diseases, Department of Dermatology, Hannover
08/1999 – 07/2001	Postdoctoral Research Fellow [funded by the Deutsche Forschungsgemeinschaft (DFG)], Department of Dermatology, Hannover
12/1996 – 12/2002	Resident & Research Assistant / Postdoctoral Research Fellow, Department of Dermatology, Hannover Medical School

Editorial Boards

Editorial Board	Associate Editor: <ul style="list-style-type: none"> • Frontiers in Immunology (section Inflammation; 2017- 12/2019) • JDDG (2017 – 2020) Section Editor <ul style="list-style-type: none"> • Journal Investigative Dermatology (since 5/2019)
-----------------	---

Selected current research projects

	<i>Project title and Support</i>	<i>Role</i>
2015-2022	ALPHA trial (Comparison of ALitretinoin with PUVA as the first line treatment in patients with severe chronic HAnd eczema); National Institute of Health Research (NIHR) HTA, multicenter (30 UK centres)	Chief Investigator (CI)

2021 – 2024	Psoriasis Association: Can molecular epidermal analysis predict response to treatment; PhD Studentship	PI
2022-2024	Pfizer global competitive grant on tissue memory cells in atopic dermatitis	PI

Selected Publications

H-index: 38 (Scopus); ORCID: 0000-0003-2328-4926

Macleod T, Bridgewood C, Hyde I, Heague M, Helliwell P, Stacey M, **Wittmann M**. *Molecular and cellular regulation of psoriatic inflammation*. Clin Sci (Lond). 2022;136(12):935-952.

Carter LM, McGonagle D, Vital EM, **Wittmann M**. *Applying Early Intervention Strategies to Autoimmune Skin Diseases. Is the Window of Opportunity Preclinical? A Dermato-Rheumatology Perspective*. J Invest Dermatol. 2022;142(3 Pt B):944-950.

Macleod T, Berekmeri A, Bridgewood C, Stacey M, McGonagle D, **Wittmann M**. *The Immunological Impact of IL-1 Family Cytokines on the Epidermal Barrier*. Front Immunol. 2021;12:808012.

Macleod T, Ainscough JS, Hesse C, Konzok S, Braun A, Buhl AL, Wenzel J, Bowyer P, Terao Y, Herrick S, **Wittmann M**, Stacey M. *The Proinflammatory Cytokine IL-36 γ Is a Global Discriminator of Harmless Microbes and Invasive Pathogens within Epithelial Tissues*. Cell Rep. 2020;33(11):108515.

Psarras A, Alase A, Antanaviciute A, Carr IM, Md Yusof MY, **Wittmann M**, Emery P, Tsokos GC, Vital EM. *Functionally impaired plasmacytoid dendritic cells and non-haematopoietic sources of type I interferon characterize human autoimmunity*. Nat Commun. 2020;11(1):6149.

Berekméri A, Tiganescu A, Alase AA, Vital E, Stacey M, **Wittmann M**. *Non-invasive Approaches for the Diagnosis of Autoimmune/Autoinflammatory Skin Diseases-A Focus on Psoriasis and Lupus erythematosus*. Front Immunol. 2019;10:1931.

Shalhaf M, Alase AA, Berekmeri A, Md Yusof MY, Pistollic J, Goodfield MJ, bEdward S, Botchkareva NV, Stacey M, Vital EM, **Wittmann M**. *Plucked hair follicles from patients with chronic discoid lupus erythematosus show a disease-specific molecular signature*. Lupus Sci Med. 2019;6(1):e000328.

Berekméri A, Latzko A, Alase A, Macleod T, Ainscough JS, Laws P, Goodfield M, Wright A, Helliwell P, Edward S, Brown GD, Reid DM, Wenzel J, Stacey M, **Wittmann M**. *Detection of IL-36 γ through noninvasive tape stripping reliably discriminates psoriasis from atopic eczema*. J Allergy Clin Immunol. 2018;142(3):988-991.e4.

Bridgewood C, Fearnley GW, Berekmeri A, Laws P, Macleod T, Ponnambalam S, Stacey M, Graham A, **Wittmann M**. *IL-36 γ Is a Strong Inducer of IL-23 in Psoriatic Cells and Activates Angiogenesis*. Front Immunol. 2018;9:200.

Ainscough JS, Macleod T, McGonagle D, Brakefield R, Baron JM, Alase A, **Wittmann M**, Stacey M. *Cathepsin S is the major activator of the psoriasis-associated proinflammatory cytokine IL-36 γ* . Proc Natl Acad Sci U S A. 2017;114(13):E2748-E2757.

Alase AA, El-Sherbiny YM, Vital EM, Tobin DJ, Turner NA, **Wittmann M**. *IFN λ Stimulates MxA Production in Human Dermal Fibroblasts via a MAPK-Dependent STAT1-Independent Mechanism*. J Invest Dermatol. 2015;135(12):2935-2943.